高通量克隆形成存活筛选鉴定放化疗增敏剂
该研究设计并优化了高通量、高内涵的克隆形成实验平台,用于从多种CTEP药物中无偏筛选与放化疗联合的最佳增敏剂,并在KRAS突变非小细胞肺癌和胰腺导管腺癌细胞系中鉴定出曲美替尼为强效放化疗增敏剂。
要点
- 建立标准化高通量克隆形成筛选平台,可跨药物比较并评估放化疗或单纯放疗效果。
- 该平台在KRAS突变非小细胞肺癌和胰腺导管腺癌细胞系中鉴定曲美替尼为强效放化疗增敏剂。
- 方法支持不同浓度和给药时序的测试,加速候选药物向临床转化。
核心结论
- 高通量、高内涵克隆形成药物筛选实验可快速鉴定放化疗增敏靶点与药物,助力改善实体瘤标准放化疗疗效。
研究设计与样本
- 研究设计、优化并验证了高通量、高内涵克隆形成实验平台,用于非小细胞肺癌和胰腺导管腺癌的临床前研究从体外向体内逐步推进。
主要发现
- 该体外方法在96孔板中无偏筛选多种CTEP药物,鉴定出最可能与放化疗联合的药物。
- 方法可无缝测试多种药物进行交叉比较,评估放化疗或单纯放疗,以及测试不同浓度和放疗前后不同时序。
- 在KRAS突变非小细胞肺癌和胰腺导管腺癌细胞系中,曲美替尼被鉴定为强效放化疗增敏剂。
临床怎么用
- 该平台可用于快速筛选和鉴定放化疗增敏剂,推动候选药物向临床转化以改善实体瘤标准放化疗效果。
局限性
- 原文指出,向大型昂贵且最终失败的临床试验转化存在差距,部分反映了临床前数据设计、执行和报告不一致的缺陷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The combination of cytotoxic chemotherapy with radiation therapy (CRT) has resulted in significant improvements in clinical outcomes for patients with many locally advanced unresectable cancers. Only a small proportion of patients achieve pathologic complete responses to CRT; combination of CRT with targeted agents offers the promise of further improving treatment responses. However, numerous clinical trials have failed to show an improvement in clinical outcomes with the addition of targeted agents. To increase the accessibility of our screening method and accelerate the pace at which novel combinations with CRT are identified and incorporated into standard practices for treatments, we report details on screening method optimization, data generation, and downstream data analysis. METHODS: In part, the gap in translation to large, expensive, and ultimately unsuccessful clinical trials reflects the shortcomings of inconsistently designed, executed, and reported preclinical data on which these studies are based. In an effort to standardize the selection of agents for future clinical testing, we have designed, optimized and validated a high throughput, high content, clonogenic assay platform for step-wise progression of preclinical studies from in vitro to in vivo in non-small cell lung cancer and pancreatic ductal adenocarcinoma. RESULTS: This highly stable in vitro method was standardized for identification of the most promising CTEP drugs that could best be combined with CRT from among as screen of multiple agents tested in an unbiased manner using 96-well plates. The methodology lends itself to seamless testing of multiple agents in a similar fashion allowing cross-comparisons, evaluation of CRT, or radiation therapy alone, and testing multiple concentrations of test agents sequenced at different times before and after radiation. The method identified Trametinib as a strong CRT sensitizer in KRAS-mutant non-small cell lung cancer and pancreatic ductal adenocarcinoma cell lines. This platform has enabled the screening and identification of several chemoradiation sensitizers. CONCLUSIONS: High throughput, high content clonogenic drug screening assay allows for the rapid identification of targets and agents to be translated to the clinic to help improve the effectiveness of current standard of care CRT in various solid tumors.
引用
- Ye R, Qiao Y, Singh PK, et al. High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers. Int J Radiat Oncol Biol Phys. 2021. PMID: 34348174. doi:10.1016/j.ijrobp.2021.07.1712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。